Sandoz has announced plans to expand its biosimilars offerings within the next five years, including a total of 11 filings by the end of 2017, and 5 launches by 2020. Sandoz says that its next five launches will be biosimilars to Enbrel® (etanercept), Humira® (adalimumab), Neulasta ® (pegfilgrastim), Remicade® (infliximab) and Rituxan® (rituximab). Sandoz has already launched its Zarxio (filgrastim) product, a biosimilar to Neupogen in the United States.